Market research

Avian Influenza Vaccines

Explore licenses

360iResearch introduction

Avian Influenza Vaccines: Executive Overview

Avian influenza remains a transboundary animal-health and food-system issue driven by viral evolution, wild-bird movements, poultry density, and international trade. Vaccination is one component of prevention and control alongside surveillance, biosecurity, movement management, rapid diagnosis, and culling where required by regulation. Policy decisions must account for protection of poultry health, reduction of clinical disease and mortality, preservation of trade confidence, and avoidance of masking infection. Human health considerations also make coordinated animal–human surveillance essential.

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to explore its complete hierarchy.

  1. Chapter 7 Vaccine Type

    • Inactivated Vaccine
    • Live Attenuated Vaccine
    • Recombinant Vaccine
    • Subunit Vaccine
    View chapter
  2. Chapter 8 Animal Type

    • Broiler Chickens
    • Layer Hens
    • Waterfowl
    View chapter
  3. Chapter 9 Application

    • Preventive
    • Therapeutic
    View chapter

Surveillance, Trade Rules, and Vaccination Are Reshaping Control

Control programs are shifting from emergency response alone toward risk-based prevention that combines vaccination with stronger biosecurity and continuous surveillance. Authorities increasingly emphasize differentiated strategies for commercial poultry, backyard flocks, and high-risk production areas. Vaccine use must be aligned with monitoring capable of distinguishing infected from vaccinated animals where applicable, documenting flock status, and supporting transparent international reporting. The landscape is also shaped by evolving standards for vaccination, product authorization, antigen matching, cold-chain management, and movement controls.

Artificial Intelligence Strengthens Detection and Operational Planning

Artificial intelligence can improve avian-influenza control by analyzing laboratory results, mortality records, production data, wildlife observations, weather patterns, and animal-movement information. Machine-learning tools may support earlier identification of unusual disease signals, prioritize field investigations, and help authorities target sampling and vaccination resources. Their value depends on representative data, validated models, interoperable reporting systems, and expert review. AI should complement-not replace-laboratory confirmation, epidemiological judgment, privacy safeguards, and transparent governance.

Regional Priorities Reflect Diverse Production and Regulatory Conditions

North America combines intensive poultry production with extensive wild-bird interfaces, making surveillance, biosecurity, and emergency preparedness central priorities. Latin America must manage varied production systems, uneven veterinary capacity, and regional trade connectivity. Europe emphasizes coordinated animal-health rules, traceability, and protection of internal and external trade. The Middle East faces differing production structures, import dependencies, and cross-border disease risks. Africa requires stronger laboratory networks, field veterinary coverage, and support for smallholder and live-bird-market systems. Asia-Pacific contains major poultry-producing areas and recurring wild-bird exposure, reinforcing the need for layered surveillance, targeted vaccination, and rapid response capacity.

Multilateral Groups Influence Coordination and Preparedness

ASEAN cooperation is relevant to cross-border surveillance, information sharing, and harmonized responses across highly connected poultry markets. BRICS members encompass substantial poultry production and diverse regulatory systems, creating opportunities for technical collaboration while requiring attention to differing reporting and authorization practices. The European Union benefits from shared animal-health frameworks and coordinated risk management. G7 engagement can support advanced surveillance, research cooperation, and preparedness financing. GCC countries must consider import reliance, desert-border logistics, and coordinated food-security measures. NATO members may benefit from resilience planning and civil–military coordination, although animal-health authorities remain responsible for disease-control policy.

Country Conditions Shape Vaccine Deployment and Surveillance

Australia prioritizes biosecurity and rapid containment because of geographic isolation and sensitive poultry and export systems. Brazil combines large-scale poultry production with extensive trade exposure, making surveillance and compartment-level assurance important. Canada and the United States must manage recurring wild-bird risks across large territories and complex poultry supply chains. China and India require approaches suited to major poultry populations, diverse farm structures, and varied local veterinary capacity. France, Germany, Italy, and Spain operate within coordinated European animal-health requirements while addressing dense production and migratory-bird pathways. Japan and South Korea emphasize preparedness, border controls, and rapid response. Mexico faces regional trade integration and varied production systems. Russia must address broad geography, migratory routes, and veterinary coordination. The United Kingdom relies on strong surveillance, biosecurity, and movement controls across distinct administrative settings.

Priorities for Leaders: Integrate Vaccination With Measurable Controls

Industry leaders should treat vaccination as part of a documented prevention system rather than a standalone intervention. They should map exposure pathways, segment flocks by risk, maintain auditable cold chains, and pair immunization with routine virological surveillance and biosecurity verification. Programs should define measurable triggers for intensified sampling, movement restrictions, and veterinary escalation. Leaders should also maintain transparent records that support trade discussions, worker protection, and public-health coordination. Investments in interoperable data systems, validated diagnostics, trained personnel, and scenario exercises can improve readiness while reducing operational delays.

Methodology: Evidence-Based Synthesis of Disease-Control Drivers

This executive summary uses a structured qualitative synthesis of authoritative animal-health and public-health guidance, regulatory frameworks, surveillance principles, and peer-reviewed evidence concerning avian influenza prevention and control. Analysis considered epidemiology, poultry-production systems, wild-bird interfaces, vaccination governance, diagnostics, trade requirements, regional coordination, and digital technologies. Geographic and group comparisons were developed from documented institutional roles and known disease-control conditions. No market estimates, market shares, forecasts, or unsupported commercial claims were used.

Conclusion: Resilient Control Requires Layered, Coordinated Action

Avian-influenza vaccine policy is most effective when embedded in a broader system of surveillance, biosecurity, diagnostics, traceability, and rapid response. Regional and national conditions differ, but the core requirements are consistent: risk-based planning, credible monitoring, regulatory alignment, and cooperation across animal, environmental, trade, and public-health authorities. Leaders that build evidence-led vaccination programs and maintain operational transparency will be better positioned to limit disease impact while protecting poultry welfare, food-system continuity, and confidence in international trade.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Avian Influenza Vaccines Market, by Vaccine Type
    1. 7.1Introduction
    2. 7.2Inactivated Vaccine
    3. 7.3Live Attenuated Vaccine
    4. 7.4Recombinant Vaccine
    5. 7.5Subunit Vaccine
  8. 8.Avian Influenza Vaccines Market, by Animal Type
    1. 8.1Introduction
    2. 8.2Broiler Chickens
    3. 8.3Layer Hens
    4. 8.4Waterfowl
  9. 9.Avian Influenza Vaccines Market, by Application
    1. 9.1Introduction
    2. 9.2Preventive
      1. 9.2.1Booster
      2. 9.2.2Primary
    3. 9.3Therapeutic
  10. 10.Avian Influenza Vaccines Market, by Administration Route
    1. 10.1Introduction
    2. 10.2Drinking Water
    3. 10.3Intramuscular
    4. 10.4Spray
    5. 10.5Subcutaneous
  11. 11.Avian Influenza Vaccines Market, by Virus Strain
    1. 11.1Introduction
    2. 11.2H5N1
    3. 11.3H7N9
    4. 11.4H9N2
  12. 12.Avian Influenza Vaccines Market, by Region
    1. 12.1Introduction
    2. 12.2Asia-Pacific
    3. 12.3North America
    4. 12.4Latin America
    5. 12.5Europe
    6. 12.6Middle East
    7. 12.7Africa
  13. 13.Avian Influenza Vaccines Market, by Group
    1. 13.1Introduction
    2. 13.2ASEAN
    3. 13.3GCC
    4. 13.4European Union
    5. 13.5BRICS
    6. 13.6G7
    7. 13.7NATO
  14. 14.Avian Influenza Vaccines Market, by Country
    1. 14.1Introduction
    2. 14.2United States
    3. 14.3Canada
    4. 14.4Mexico
    5. 14.5Brazil
    6. 14.6United Kingdom
    7. 14.7Germany
    8. 14.8France
    9. 14.9Russia
    10. 14.10Italy
    11. 14.11Spain
    12. 14.12China
    13. 14.13India
    14. 14.14Japan
    15. 14.15Australia
    16. 14.16South Korea
  15. 15.Competitive Landscape
    1. 15.1Market Share Analysis, 2025
    2. 15.2Market Concentration Analysis, 2025
      1. 15.2.1Concentration Ratio (CR)
      2. 15.2.2Herfindahl Hirschman Index (HHI)
    3. 15.3Recent Developments & Impact Analysis, 2025
    4. 15.4Product Portfolio Analysis, 2025
    5. 15.5Benchmarking Analysis, 2025
  16. 16.Company Profiles
    1. 16.1AdvaCare Pharma Pte. Ltd.
    2. 16.2AstraZeneca PLC
    3. 16.3Bharat Biotech International Limited
    4. 16.4BioNTech SE
    5. 16.5Boehringer Ingelheim International GmbH
    6. 16.6CAVAC S.A.
    7. 16.7Ceva Santé Animale S.A.
    8. 16.8Chengdu Tech-bank Biological Products Co., Ltd
    9. 16.9CSL Limited
    10. 16.10Daiichi Sankyo Company, Limited
    11. 16.11Elanco Animal Health Incorporated
    12. 16.12Emergent BioSolutions Inc.
    13. 16.13Fatro S.P.A.
    14. 16.14GlaxoSmithKline plc
    15. 16.15Hester Biosciences Limited
    16. 16.16HIPRA S.L.
    17. 16.17Johnson & Johnson Private Limited
    18. 16.18Medion S.A.
    19. 16.19Merck & Co., Inc.
    20. 16.20Mitsubishi Tanabe Pharma Corporation
    21. 16.21Moderna, Inc.
    22. 16.22Novavax, Inc.
    23. 16.23Pfizer Inc.
    24. 16.24Phibro Animal Health Corporation
    25. 16.25QYH Biotech Company Limited
    26. 16.26Sanofi S.A.
    27. 16.27Seqirus UK Limited
    28. 16.28Serum Institute of India Private Limited
    29. 16.29Sinovac Biotech Ltd.
    30. 16.30Vaxart, Inc.
    31. 16.31Virbac S.A.
    32. 16.32Zoetis Inc
  17. 17.Key Experts

Loading the sample request form…